Citadel Advisors
MLYS icon

Citadel Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Citadel Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Sell
52,600
-21,000
-29% -$576K ﹤0.01% 7351
2026
Q1 		$1.99M Buy
73,600
+38,400
+109% +$1.13M ﹤0.01% 6071
2025
Q4 		$1.28M Sell
35,200
-16,700
-32% -$670K ﹤0.01% 6874
2025
Q3 		$1.97M Buy
+51,900
New +$1.12M ﹤0.01% 6100
2025
Q2 		– Sell
-52,200
Closed -$829K – 14091
2025
Q1 		$829K Buy
+52,200
New +$600K ﹤0.01% 7367
2024
Q4 		– Sell
-4,800
Closed -$58.1K – 15054
2024
Q3 		$58.1K Buy
4,800
+3,200
+200% +$38.7K ﹤0.01% 11742
2024
Q2 		$18.7K Sell
1,600
-4,700
-75% -$59.2K ﹤0.01% 12700
2024
Q1 		$81.3K Buy
+6,300
New +$77.8K ﹤0.01% 11632

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors's MLYS Position: Q2 2026 in Review

Citadel Advisors reduced its Mineralys Therapeutics (MLYS) stake by 22% in Q2 2026, selling an estimated $3.63M and leaving 467,598 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3219.

Citadel Advisors first reported a position in MLYS in Q1 2023 and has held it in 12 quarters since. The position peaked at $78.4M in Q3 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Citadel Advisors held 467,598 shares of Mineralys Therapeutics worth $12.6M as of Q2 2026.
  • Citadel Advisors sold 132,443 Mineralys Therapeutics shares in Q2 2026, an estimated $3.63M.
  • Mineralys Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3219 holding.
  • Citadel Advisors first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Citadel Advisors's Mineralys Therapeutics position peaked at $78.4M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.